Business
Medical Marijuana, Inc. Investment Company Kannalife, Inc. Appoints Terrence O. Tormey to Board of Advisors
Medical Marijuana, Inc. Investment Company Kannalife, Inc. Appoints Terrence O. Tormey to Board of Advisors.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Investment Company Kannalife, Inc. Appoints Terrence O. Tormey to Board of Advisors\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Investment Company Kannalife, Inc. Appoints Terrence O. Tormey to Board of Advisors\nPR Newswire\nSAN DIEGO, June 4, 2020\n\n\n\nSAN DIEGO, June 4, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company Kannalife, Inc. (\"Kannalife\") (OTCQB: KLFE) has appointed biotechnology and pharmaceutical industry veteran Terrence O. Tormey to the company's Board of Advisors.\n\"Kannalife continues to prove itself as a leader in cannabinoid research and its reputation to add well-respected biotech and pharmaceutical leaders like Terrence Tormey to its team amplifies its efforts,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \n\"It's an honor to have Terry join our advisory board because his experience, vision and knowledge in the life sciences industry will help us start to design our commercialization and distribution plan for Atopidine™,\" said Dean Petkanas, CEO of Kannalife.\nMr. Tormey brings over four decades of experience in the life sciences industry and has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson). Most recently he was the CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease.\n\"I am honored to serve as an advisor to Kannalife. The company has remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Pe...